Gelesis to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Gelesis (NYSE: GLS) announced that its CEO Yishai Zohar, CFO Elliot Maltz, and COO David Pass will participate in two upcoming investor conferences. The first event is the UBS Global Healthcare Conference on May 25, 2022, with a presentation at 8:30 a.m. ET. Attendees can join the live webcast here.

The second event is the Loop Capital Conference on June 1, 2022, participated virtually. Gelesis is known for Plenity, a FDA-cleared solution for weight management.

BOSTON--(BUSINESS WIRE)-- Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Officer, Elliot Maltz, Chief Financial Officer, and David Pass, Chief Operating and Commercial Officer, will participate in two upcoming investor conferences:

(Photo: Business Wire)

Wednesday, May 25, 2022: UBS Global Healthcare Conference: Gelesis will host a presentation beginning at 8:30 a.m. Eastern Time. The presentation will be webcast live here and on the Company’s investor relations website at ir.gelesis.com.

Wednesday, June 1, 2022: Third Annual Loop Capital Conference: Gelesis will participate virtually. Please contact your Loop Capital representative for further details.

About Gelesis

Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis”) is a consumer-centered biotherapeutics company and the maker of Plenity®, which is inspired by nature and FDA cleared to aid in weight management. Our first-of-their-kind non-systemic superabsorbent hydrogels are made entirely from naturally derived building blocks. They are inspired by the composition and mechanical properties of raw vegetables, taken by capsule, and act locally in the digestive system, so people feel satisfied with smaller portions. Our portfolio includes Plenity® and potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation. For more information, visit gelesis.com, or connect with us on Twitter @GelesisInc.

Plenity® is indicated to aid weight management in adults with excess weight or obesity, a Body Mass Index (BMI) of 25–40 kg/m², when used in conjunction with diet and exercise.

Important Safety Information about Plenity

• Patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide should not take Plenity.
• To avoid impact on the absorption of medications:
  • For all medications that should be taken with food, take them after starting a meal.
  • For all medications that should be taken without food (on an empty stomach), continue taking on an empty stomach or as recommended by your physician.
• The overall incidence of side effects with Plenity was no different than placebo. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence.
• Contact a doctor right away if problems occur. If you have a severe allergic reaction, severe stomach pain, or severe diarrhea, stop using Plenity until you can speak to your doctor.

Rx Only. For the safe and proper use of Plenity or more information, talk to a healthcare professional, read the Patient Instructions for Use, or call 1-844-PLENITY.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220518006013/en/

Media & Investor Relations

Katie Sullivan

ksullivan@gelesis.com

Source: Gelesis Holdings, Inc.

FAQ

When will Gelesis participate in the UBS Global Healthcare Conference?

Gelesis will participate in the UBS Global Healthcare Conference on May 25, 2022, starting at 8:30 a.m. ET.

What is the date for the Loop Capital Conference involving GLS?

Gelesis will participate in the Loop Capital Conference on June 1, 2022.

Where can I watch the Gelesis presentation during the UBS Conference?

The Gelesis presentation can be watched live via webcast here.

What is Gelesis known for?

Gelesis is known for Plenity, a FDA-cleared weight management solution.

Who are the executives participating in the investor conferences for GLS?

The executives participating are Yishai Zohar (CEO), Elliot Maltz (CFO), and David Pass (COO).